An interventional study of Traditional Therapy and SWAN in Vestibular Disorder, Vestibular Schwannoma and Space Motion Sickness, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.
The rehabilitation device guides users to perform sinusoidal head rotations, matched to a metronome, about the yaw, pitch, and roll axes (60 sec epochs, 5 minutes per axis, 15 min total). The assessment for each axis consists of the number of completed epochs with each epoch requiring head rotations of a different amplitude. Subjects are instructed to begin with an 'easy' amplitude (i.e. small) and increase or decrease amplitude depending on the subject's perception of motion sickness - which is input from 0 (absent motion sick) to 11 (vomit) using a handheld controller. Video-oculography captures eye and head velocity as well as tracks the number of blinks and saccades, metrics that can indicate worsening nausea.
170 studies on the registry are indexed under Vestibular Diseases; 41 are open to participants now.
This study's planned enrollment of 48 is close to the median of 46 across 127 interventional studies indexed under Vestibular Diseases.
Browse Vestibular Diseases studies →Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects that have had their eighth cranial nerve resected will receive traditional vestibular rehabilitation exercises at Johns Hopkins University (JHU) site.
Behavioral: Traditional Therapy
Subjects that have had their eighth cranial nerve resected will receive the automated vestibular rehabilitation method
Device: SWAN
Healthy control subjects that meet similar similar physical characteristics of astronauts will receive the automated vestibular rehabilitation method post motion sickness.
Device: SWAN
Typically, the suggestion for treating motion sickness once it has started is to avoid motion. Therefore, healthy control subjects that meet similar similar physical characteristics of astronauts will not receive any post motion sickness treatment.
Exercises that teaches subjects to move their heads while viewing still or moving targets.
Also known as: Gaze stability exercises
The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
Also known as: StableEyes Training Device with video-oculography
Change in Motion sickness intensity as assessed by subjective rating
Subjective rating of motion sickness intensity from 0 to 10. Zero denotes absent motion sickness while 10 denote vomiting.
Time frame: Daily for up to 4 weeks
Change in Vestibulo-Ocular Reflex (VOR) gain as measured by video-oculography
Ratio of eye velocity to head velocity that varies from 0 to 1.2. Normal scores are greater than 0.8.
Time frame: Daily for up to 4 weeks
Change in Number of blinks as measured by video-oculography
Increase blinking is correlated with worse motion sickness.
Time frame: Daily for up to 4 weeks
Change in Heart rate as measured by a monitor worn over the forearm
Heart rate in beats per minute will be measured using a monitor worn over the forearm.
Time frame: Daily for up to 4 weeks
Change in Timed Up and Go Plus
Time measured in seconds for a subject to stand up, step over an obstacle then walk 3M before turning around and sitting down.
Time frame: Daily for up to 4 weeks
Change in Foam Stance - Eyes Open
Time in seconds to stand on foam with eyes open. Inability to stand for less than 20 seconds is associated with 3x greater risk for falling.
Time frame: Daily for up to 4 weeks
Change in Foam Stance - Eyes Closed
Time in seconds to stand on foam with eyes closed. Inability to stand for less than 20 seconds is associated with 3x greater risk for falling.
Time frame: Daily for up to 4 weeks
Change in Foam Stance - Eyes Open with head motion
Time to seconds to stand on foam with eyes open while moving head up and down. Inability to stand for less than 20 seconds is associated with 3x greater risk for falling.
Time frame: Daily for up to 4 weeks
Change in Foam Stance - Eyes Closed with head motion
Time in seconds to stand on foam with eyes closed while moving head up and down. Inability to stand for less than 20 seconds is associated with 3x greater risk for falling.
Time frame: Daily for up to 4 weeks
Change in Gait speed
Velocity to walk 6m within a 10m marked distance, measured in meters/second. Normative data exists based on decade of age.
Time frame: Daily for up to 4 weeks
Change in Gait endurance
Distance walked in 2 minutes, measure in meters.
Time frame: Daily for up to 4 weeks
Change in Vertical and torsional alignment nulling test (VAN and TAN)
Vertical alignment nulling and torsional alignment nulling ask subjects to adjust lines to there perceived horizontal. Measured in degrees.
Time frame: Daily for up to 4 weeks
Change in Rod and Frame Test
Subjects adjust a virtual line to their perceived vertical, measured in degrees.
Time frame: Daily for up to 4 weeks
Change in Rod and Disk Test
Subjects adjust a virtual line to their perceived vertical, measured in degrees.
Time frame: Daily for up to 4 weeks
Change in Subjective Visual Vertical
Subjects adjust a virtual line to their perceived vertical, measured in degrees.
Time frame: Daily for up to 4 weeks
Change in Daily Activity as assessed by an activity monitor
Subjects wear an activity monitor on their wrist Data includes daily distance walked .
Time frame: Daily for up to 4 weeks
Plan to share: No — Currently, we have no plan to share data with other researchers
Started Aug 2022 (actual). Primary completion is estimated for Mar 2027, 55 months after the start.
Of 79 non-industry interventional studies with no phase under Vestibular Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's planned 55 months is above that.
Counting every sponsor, half of 84 studies reached it within 15 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.